Current situation and future usage of anticancer drug databases

被引:14
作者
Wang, Hongzhi [1 ]
Yin, Yuanyuan [2 ]
Wang, Peiqi [2 ]
Xiong, Chenyu [3 ,4 ,5 ,6 ]
Huang, Lingyu [3 ,4 ,5 ,6 ]
Li, Sijia [2 ]
Li, Xinyi [2 ]
Fu, Leilei [4 ,5 ,6 ]
机构
[1] Tonghua Normal Univ, Coll Math, Tonghua 134002, Peoples R China
[2] Sichuan Univ, West China Hosp Stomatol, State Key Lab Oral Dis, Chengdu 610041, Peoples R China
[3] Sichuan Univ, Coll Life Sci, Chengdu 610064, Peoples R China
[4] Sichuan Univ, West China Hosp, State Key Lab Biotherapy, Chengdu 610041, Peoples R China
[5] Sichuan Univ, West China Hosp, Ctr Canc, Chengdu 610041, Peoples R China
[6] Collaborat Innovat Ctr Biotherapy, Chengdu 610041, Peoples R China
基金
中国博士后科学基金;
关键词
Anticancer drugs; Databases; Targeted therapy; Drug discovery; SYNTHETIC LETHALITY; CANCER; DISCOVERY; RESISTANCE; RESOURCE; TARGET; SENSITIVITY; EXPRESSION; BIOMARKERS; PEPTIDES;
D O I
10.1007/s10495-016-1250-5
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Cancer is a deadly disease with increasing incidence and mortality rates and affects the life quality of millions of people per year. The past 15 years have witnessed the rapid development of targeted therapy for cancer treatment, with numerous anticancer drugs, drug targets and related gene mutations been identified. The demand for better anticancer drugs and the advances in database technologies have propelled the development of databases related to anticancer drugs. These databases provide systematic collections of integrative information either directly on anticancer drugs or on a specific type of anticancer drugs with their own emphases on different aspects, such as drug-target interactions, the relationship between mutations in drug targets and drug resistance/sensitivity, drug-drug interactions, natural products with anticancer activity, anticancer peptides, synthetic lethality pairs and histone deacetylase inhibitors. We focus on a holistic view of the current situation and future usage of databases related to anticancer drugs and further discuss their strengths and weaknesses, in the hope of facilitating the discovery of new anticancer drugs with better clinical outcomes.
引用
收藏
页码:778 / 794
页数:17
相关论文
共 50 条
  • [41] USE OF LARGE COMBINATORIAL CHEMICAL LIBRARIES FOR ANTICANCER DRUG DISCOVERY
    SALMON, SE
    LAM, KS
    FELDER, S
    YEOMAN, H
    SCHLESSINGER, J
    ULLRICH, A
    KRCHNAK, V
    LEBL, M
    INTERNATIONAL JOURNAL OF PHARMACOGNOSY, 1995, 33 : 67 - 74
  • [42] What value do zebrafish have to anticancer drug discovery?
    Xiao, Boyuan
    Landesman-Bollag, Esther
    Feng, Hui
    EXPERT OPINION ON DRUG DISCOVERY, 2024, 19 (04) : 369 - 375
  • [43] DENDRIMERS IN ANTICANCER TARGETED DRUG DELIVERY: ACCOMPLISHMENTS, CHALLENGES AND DIRECTIONS FOR FUTURE
    Amjad, M. W.
    PHARMACY & PHARMACOLOGY-FARMATSIYA I FARMAKOLOGIYA, 2021, 9 (01): : 4 - 16
  • [44] Critical Appraisal and Future Challenges of Artificial Intelligence and Anticancer Drug Development
    Chamorey, Emmanuel
    Gal, Jocelyn
    Mograbi, Baharia
    Milano, Gerard
    PHARMACEUTICALS, 2024, 17 (07)
  • [45] DRPreter: Interpretable Anticancer Drug Response Prediction Using Knowledge-Guided Graph Neural Networks and Transformer
    Shin, Jihye
    Piao, Yinhua
    Bang, Dongmin
    Kim, Sun
    Jo, Kyuri
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (22)
  • [46] Autophagy and cancer: Can tetrandrine be a potent anticancer drug in the near future?
    Bhagya, N.
    Chandrashekar, K. R.
    BIOMEDICINE & PHARMACOTHERAPY, 2022, 148
  • [47] Mechanistic study of cancer drug delivery: Current techniques, limitations, and future prospects
    Imtiaz, Saiqa
    Ferdous, Umme Tamanna
    Nizela, Alexis
    Hasan, Anwarul
    Shakoor, Adnan
    Zia, Abdul Wasy
    Uddin, Shihab
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2025, 290
  • [48] Nonalcoholic fatty liver disease: Current therapies and future perspectives in drug delivery
    Domingues, Ines
    Leclercq, Isabelle A.
    Beloqui, Ana
    JOURNAL OF CONTROLLED RELEASE, 2023, 363 : 415 - 434
  • [49] Clinical utility of microRNAs in renal cell carcinoma: current evidence and future perspectives
    Tsiakanikas, Panagiotis
    Giaginis, Constantinos
    Kontos, Christos K.
    Scorilas, Andreas
    EXPERT REVIEW OF MOLECULAR DIAGNOSTICS, 2018, 18 (11) : 981 - 991
  • [50] Omics Approaches in Drug Development against Leishmaniasis: Current Scenario and Future Prospects
    Rabaan, Ali A.
    Bakhrebah, Muhammed A.
    Mohapatra, Ranjan K.
    Farahat, Ramadan Abdelmoez
    Dhawan, Manish
    Alwarthan, Sara
    Aljeldah, Mohammed
    Al Shammari, Basim R.
    Al-Najjar, Amal H.
    Alhusayyen, Mona A.
    Al-Absi, Ghadeer H.
    Aldawood, Yahya
    Alsaleh, Abdulmonem A.
    Alshamrani, Saleh A.
    Almuthree, Souad A.
    Alawfi, Abdulsalam
    Alshengeti, Amer
    Alwashmi, Ameen S. S.
    Hajissa, Khalid
    Nassar, Majed S.
    PATHOGENS, 2023, 12 (01):